Literature DB >> 19936129

Extended-release formulations of antiepileptic drugs: rationale and comparative value.

Emilio Perucca1.   

Abstract

Extended-release products are designed to prolong the absorption of drugs with short half-lives, thereby allowing longer dosing intervals while minimizing fluctuations in serum drug levels. The relationship between serum drug concentration and clinical effects of antiepileptic drugs (AEDs) can be complex and reducing fluctuations in serum drug levels is not equally advantageous for all AEDs. Extended-release formulations have been shown to be particularly valuable for carbamazepine, whereas for other AEDs advantages, other than prolongation of the dosing interval, have not been clearly demonstrated. Differences in bioavailability may exist between extended-release and immediate-release formulations and among different brands of extended-release products. Therefore, when switching from one formulation to another, careful monitoring of clinical response and attention to the need for dose adjustment are warranted.

Entities:  

Year:  2009        PMID: 19936129      PMCID: PMC2778358          DOI: 10.1111/j.1535-7511.2009.01326.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN: 1535-7511            Impact factor:   7.500


  42 in total

1.  Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations.

Authors:  O Eeg-Olofsson; H L Nilsson; B Tonnby; J Arvidsson; P A Grahn; H Gylje; C Larsson; L Norén
Journal:  J Child Neurol       Date:  1990-04       Impact factor: 1.987

2.  Once-daily sodium valproate in the treatment of epilepsy.

Authors:  A Covanis; P M Jeavons
Journal:  Dev Med Child Neurol       Date:  1980-04       Impact factor: 5.449

3.  Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects.

Authors:  R J Höppener; A Kuyer; J W Meijer; J Hulsman
Journal:  Epilepsia       Date:  1980-08       Impact factor: 5.864

4.  Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group.

Authors:  R C Sachdeo; R F Leroy; G L Krauss; M E Drake; P M Green; I E Leppik; V S Shu; G L Ringham; K W Sommerville
Journal:  Arch Neurol       Date:  1997-05

5.  Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group.

Authors:  M J Brodie; P W Overstall; L Giorgi
Journal:  Epilepsy Res       Date:  1999-10       Impact factor: 3.045

6.  Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam.

Authors:  D G Kasteleijn-Nolst Trenité; C Marescaux; S Stodieck; P M Edelbroek; J Oosting
Journal:  Epilepsy Res       Date:  1996-11       Impact factor: 3.045

7.  Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures.

Authors:  Manon Thibault; Warren T Blume; Jean-Marc Saint-Hilaire; Rafik Zakhari; Kenneth W Sommerville
Journal:  Epilepsy Res       Date:  2002-08       Impact factor: 3.045

Review 8.  Pharmacology and clinical pharmacology of vigabatrin.

Authors:  A Richens
Journal:  J Child Neurol       Date:  1991       Impact factor: 1.987

9.  Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.

Authors:  K M Thakker; S Mangat; W R Garnett; R H Levy; G M Kochak
Journal:  Biopharm Drug Dispos       Date:  1992-11       Impact factor: 1.627

10.  Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model.

Authors:  D G A Kasteleijn-Nolst Trenité; P Genton; D Parain; P Masnou; B J Steinhoff; T Jacobs; E Pigeolet; A Stockis; E Hirsch
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

View more
  8 in total

1.  Epidural administration of neostigmine-loaded nanofibers provides extended analgesia in rats.

Authors:  Masoomeh Yosefifard; Majid Hassanpour-Ezatti
Journal:  Daru       Date:  2014-11-18       Impact factor: 3.117

2.  Ghost-Pill-Buster: A Case Study of Intact Levetiracetam Extended-Release Tablets after Dissolution Testing.

Authors:  Dajun Sun; Hong Wen; Anna Externbrink; Zongming Gao; David Keire; Gregory Krauss; Wenlei Jiang
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 3.  A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy.

Authors:  James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jul-Aug

4.  Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial.

Authors:  J A French; P Baroldi; S T Brittain; J K Johnson
Journal:  Acta Neurol Scand       Date:  2013-12-21       Impact factor: 3.209

5.  USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers.

Authors:  Annie M Clark; Mark B Halvorsen; Tricia L Braun; Krista M Johnson; James C Cloyd
Journal:  Epilepsia       Date:  2014-05-23       Impact factor: 5.864

6.  Pharmacokinetic characteristics of antiepileptic drugs (AEDs).

Authors:  Marketa Marvanova
Journal:  Ment Health Clin       Date:  2016-03-08

7.  Preparation and characterisation of PHT-loaded chitosan lecithin nanoparticles for intranasal drug delivery to the brain.

Authors:  Amal Yousfan; Noelia Rubio; Abdul Hakim Natouf; Aamal Daher; Nedal Al-Kafry; Kerrie Venner; Houmam Kafa
Journal:  RSC Adv       Date:  2020-08-05       Impact factor: 4.036

Review 8.  Not all that glitters is gold: A guide to the critical interpretation of drug trials in epilepsy.

Authors:  Emilio Perucca; Samuel Wiebe
Journal:  Epilepsia Open       Date:  2016-07-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.